Payment overview · 2025
General Payments
$970.04
49 reported records · 17 companies
Healthcare provider profile · identity verified
Mohamad Badaoui
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GARDEN CITY, MI · NPI 1659004919
Verified facts
What the public records show
CMS Open Payments records show Mohamad Badaoui received $970.04 in general payments during 2025 across 49 reported records.
ABBVIE INC. accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vraylar by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Xarelto by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $220.19 | 22.7% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $152.74 | 15.8% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $112.66 | 11.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $76.87 | 7.9% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $57.86 | 6.0% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.75 | 4.5% | 2 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $43.27 | 4.5% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $41.40 | 4.3% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.07 | 4.0% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $34.61 | 3.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.33 | 3.3% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $27.79 | 2.9% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.90 | 2.6% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $18.41 | 1.9% | 1 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $15.87 | 1.6% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $14.60 | 1.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $13.72 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $970.04 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $220.19 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $141.33 | 6 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $124.07 | 6 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $124.07 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $76.87 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $57.86 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $43.27 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $41.40 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $39.07 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.33 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trazodone Hcl | Trazodone Hcl | 221 | 46 |
| Alprazolam | Alprazolam | 220 | 35 |
| Atorvastatin Calcium | Atorvastatin Calcium | 198 | 46 |
| Mirtazapine | Mirtazapine | 178 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 171 | 36 |
| Omeprazole | Omeprazole | 148 | 31 |
| Furosemide | Furosemide | 147 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 133 | 24 |
| Gabapentin | Gabapentin | 123 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 111 | 23 |
| Lisinopril | Lisinopril | 111 | 25 |
| Sertraline Hcl | Sertraline Hcl | 109 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 21 |
| Metformin Hcl | Metformin Hcl | 105 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 27 |
| Clonazepam | Clonazepam | 96 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 16 |
| Eliquis | Apixaban | 81 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 78 | 13 |
| Losartan Potassium | Losartan Potassium | 78 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 12 |
| Ketoconazole | Ketoconazole | 71 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 70 | 23 |
| Allopurinol | Allopurinol | 69 | suppressed |
| Carvedilol | Carvedilol | 68 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 15 |
| Simvastatin | Simvastatin | 66 | 15 |
| Donepezil Hcl | Donepezil Hcl | 64 | 12 |
| Famotidine | Famotidine | 62 | 12 |
| Ibuprofen | Ibuprofen | 62 | 12 |
| Lorazepam | Lorazepam | 60 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 17 |
| Potassium Chloride | Potassium Chloride | 57 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 16 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 52 | 14 |
| Montelukast Sodium | Montelukast Sodium | 49 | 12 |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Aripiprazole | Aripiprazole | 44 | 14 |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 42 | suppressed |
| Lamotrigine | Lamotrigine | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Olanzapine | Olanzapine | 37 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Nystatin | Nystatin | 33 | suppressed |
| Latanoprost | Latanoprost | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 29 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 29 | suppressed |
| Vraylar | Cariprazine Hcl | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Comfort Touch Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $970.04 · 49 records | ABBVIE INC. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, Dyanavel XR, ERZOFRI EXTENDED-RELEASE, FANAPT, INGREZZA, Jornay PM, LYBALVI, Qelbree, REXULTI, SPRAVATO, VRAYLAR, Xelstrym, ZURZUVAE, Zubsolv | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error